Effect Index serves as the platform for the Subjective Effect Index (SEI), a resource containing formalised documentation of the vast number of distinct subjective states that may occur under the influence of hallucinogens. We strive to comprehensively document and describe the wide variety of potential hallucinogenic experiences. The SEI is presented in an easily readable format that contains not only descriptions, but also image, video, and audio replications of these effects. We believe that in pioneering formalised subjective effect documentation, we may demystify the psychedelic experience. This has the potential to allow hallucinogen usage to become more culturally acceptable, better understood, and create a platform on top of which these substances may be more easily studied. Effect Index was initially founded as a side project on 30 June, 2017 by Josie Kins, the founder of PsychonautWiki and DisregardEverythingISay. It serves as a platform for content that has been in constant development for the previous six years on these sites. However, the aforementioned content is now hosted on its own dedicated platform with the hope of further spreading the documentation and creating a universal terminology set that gives people the vernacular to fully describe experiences that were previously considered ineffable.
The Cost of Exclusion in Psychedelic Research
In the last two decades, researchers have started to reexamine psychedelics for their therapeutic potential. Though initial results seem promising, the research has a significant shortcoming: the lack of racial and ethnic diversity among research teams and study participants. In the 1960s, psychedelic substances such as LSD, psilocybin, and mescaline were a major part of American counterculture. Less well-known is that, concurrently, researchers were studying potential therapeutic uses of these mind-altering substances. Unfortunately, psychedelics were classified as Schedule I drugs in 1970, halting research into their therapeutic benefits. The recent renaissance of psychedelic research shows these substances have significant capabilities for treating anxiety, depression, posttraumatic stress disorder (PTSD), and substance use disorders. But these promising results are limited in their applicability: an analysis from 2018 showed that 82.3% of all study participants in psychedelic trials internationally were non-Hispanic Whites, and only 2.5% were African-American.
Council on Spiritual Practices
The Council on Spiritual Practices is a collaboration among spiritual guides, experts in the behavioral and biomedical sciences, and scholars of religion, dedicated to making direct experience of the sacred more available to more people. There is evidence that such encounters can have profound benefits for those who experience them, for their neighbors, and for the world. CSP has a twofold mission: to identify and develop approaches to primary religious experience that can be used safely and effectively, and to help individuals and spiritual communities bring the insights, grace, and joy that arise from direct perception of the divine into their daily lives. The Council on Spiritual Practices has no doctrine or liturgy of its own.
Chacruna: Institute for Psychedelic Plant Medicines
We promote reciprocity in the psychedelic community, and support the protection of sacred plants and cultural traditions. We advance psychedelic justice through curating critical conversations and uplifting the voices of women, queer people, Indigenous peoples, people of color, and the Global South in the field of psychedelic science.
Psychedelic Experience (PEx) is a comprehensive online resource for information surrounding psychedelic substances. We are a community based non-profit organization, created by and for psychedelic and plant medicine communities. Our mission is to support and facilitate global healing and personal growth through safe, responsible and legal use of plant medicines and psychedelic-assisted treatments. We are opposed to the commercialization of psychedelics and believe that profiteering and opportunism go against the very heart of the psychedelic experience. That’s why we are a non-profit and will never be driven by corporate interests or shareholder greed. Our website and global directory service of psychedelic-related organizations seeks to promote the safe, responsible use of psychedelics. We provide accurate, evidence-based information regarding retreat centers, facilitators, shamans, therapeutic modalities, and organizations.
Our mission is to help people minimize the risks and fulfill the potential of their psychedelic experiences in ways such as providing compassionate, accessible, and culturally responsive peer support, educating the public, and furthering psychedelic research, while embracing practices that increase equity, power sharing, and belonging within the psychedelic movement.
The Zendo Project provides professional comprehensive harm reduction education and support for communities to help inform and transform difficult psychedelic experiences into opportunities for learning and growth. We envision a world where communities are educated, resourced, and engaged in applying harm reduction principles to support individuals exploring psychedelic states; recognizing that challenging experiences can be opportunities for self-exploration and healing.
Riding The Wave: Principles of Psychedelic Harm Reduction
Welcome to Riding The Wave: Principles of Psychedelic Harm Reduction, an e-course presented by Psychedelic.Support, NEST Harm Reduction, and Project New Day. In this course, you’ll explore the principles of harm reduction, their impact on psychedelic users, and risks associated with different psychedelic substances. Further, we’ll discover tangible ways to support a psychedelic experience through holistic integration and preparation techniques. By the end of this course you’ll be able to: 1) Describe the principles of harm reduction and define terminology related to psychedelic harm reduction. 2) Understand risks and potential adverse consequences of psychedelic use and how risks vary across settings and individuals. 3) Specify contraindications for each drug class and identify common harms associated with altered states. 4) Discuss harm reduction strategies and how preparation and integration can help mitigate risks. 5) Explain how clinicians can talk to clients about harm reduction and psychedelic use.